Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 31

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 31
---
 of the Channel Series A Preferred Stock to be issued in the Merger have been approved for listing on The NYSE American, subject to notice of issuance, as of the closing of the Merger. The terms of the Merger Agreement permit that this condition may be waived by agreement between Channel and LNHC, without recirculation or re-solicitation of this information statement.

| Q. | Do I need to consent or submit a proxy in relation to the Transaction Agreements, including the Transactions, the Name Change Charter Amendment, the Amended and Restated 2023 Plan and the Reverse Stock Split? |

| A. | No. Channel is not soliciting your consent or proxy in connection with the Transaction Agreements, including the Transactions, the Name Change Charter Amendment, the Amended and Restated 2023 Plan and the Reverse Stock Split, and no consents or proxies are requested from holders of Channel common stock. |

| Q. | Am I entitled to appraisal rights? |

| A. | No. The holders of shares of Channel common stock are not entitled to dissenters’ rights or to demand appraisal of, or to receive payment for, their shares of Channel common stock under the NRS in connection with the Transaction Agreements, including the Transactions. |

| Q. | Who will be the directors of the combined company following the Merger? |

| A. | Immediately following the Merger, the combined company’s board of directors will be composed of seven members, consisting of (i) four directors selected by LNHC, namely Peter Greenleaf, Matthew Pauls, Todd Davis and Richard Baxter, (ii) one director who is the intended Chief Executive Officer of the surviving corporation, namely Scott Plesha, (iii) one director selected by Channel, namely Dr. Richard Malamut and (iv) one director selected by Nomis Bay, namely Ezra Friedberg. |

15

TABLE OF CONTENTS

| Q. | Who will be the executive officers and directors of the combined company immediately following the Merger? |

| A. | Immediately following the Merger, the executive officers and directors of the combined company are expected to be: |

| Name                |     | Title                                           |
| Scott Plesha        |     | President, Chief Executive Officer and Director |
| Francis Knuettel II |     | Chief Financial Officer                         |
| Richard Baxter      |     | Director                                        |
| Todd Davis          |     | Director                                        |
| Ezra Friedberg      |     | Director                                        |
|